Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Cell Therapy
  6.  » Scale-up Strategies for Late-stage Cell Therapies

Scale-up Strategies for Late-stage Cell Therapies

Summary: The number of autologous cell therapy products commercially approved or approaching launch is growing, with allogeneic therapies very close behind. CDMOs need to ensure they are designing innovative processes and flexible facilities that can accommodate both autologous and allogeneic cell therapy products for small and large patient populations. In this webinar, we explore the considerations that need to be taken during development to ensure manufacturing processes and our facilities can support the high throughput needed to supply expanding patient populations once products reach commercial realization. ​

Click here to view the webinar